11.04.25 -- Best Practices For Program Manager Alignment And Integration When Working With A CDMO

Learn five key factors that drive a seamless technology transfer, highlighting how a culture of technical expertise, customer focus, and operational flexibility is crucial to success in the CDMO industry.

Experience the benefits of faster, more effective CAR-T cell production with this innovative three-day short-cycle process, designed to enhance patient treatment outcomes while reducing costs.

A properly executed virtual audit facilitates thorough qualification, condenses production timelines, enhances relationship-building, and provides early insight into a CDMO’s capability and expertise.

Maintaining drug product sterility and compliance demands rigorous Container Closure Integrity (CCI) within contract manufacturing. Learn how to fortify your processes.

This advanced cell line development technology overcomes production challenges related to the expression and scalability of complex biologics.

By utilizing an engineered co-transcriptional capping RNA Polymerase, researchers can reduce the production of double-stranded RNA byproducts and enhance the functionality of mRNA therapeutics.

Accelerate your path from discovery to clinic by leveraging high-quality plasmid DNA, optimized expression systems, and early developability assessments to streamline transient protein production.

Discover insights tailored specifically for drug product researchers and manufacturers, offering key knowledge on extractables, leachables, and effective implementation strategies.

Leveraging Abzena’s deep expertise in biologics development and supported by our comprehensive analytics suite, AbZelectPRO™ streamlines the IND application pathway, ensuring smooth progression into clinical phases.

In cell line development, application of targeted integration cell line technology boosts development speed. Then, a proven production platform facilitates seamless scaleup to GMP manufacturing.

Explore key strategies and technologies designed to address the analytical considerations and material flows to facilitate the rapid delivery of toxicological material.

Standardized, well-characterized plasmids and streamlined platform processes can significantly accelerate viral vector development, improve consistency, and support scalable, high-quality gene therapy manufacturing.

Review the pros and cons of soluble and insoluble processes, experiences with isolating, solubilizing, and properly re-folding, and strategies and innovation to improve insoluble processes.

Leveraging cross-functional coordination between sites, harmonized tech transfers, one quality system, and synchronized team activities can help deliver high-quality commercial outcomes.